612 related articles for article (PubMed ID: 30940117)
21. Prognostic significance of basal 18F-FDG PET / CT maximum standardized uptake value in patients with metastatic renal cell carcinoma who were treated with sunitinib.
Aytekin A; Aldemir MN; Sakin A; Telci U; Esen R
J BUON; 2020; 25(5):2490-2495. PubMed ID: 33277873
[TBL] [Abstract][Full Text] [Related]
22. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
23. Semi-quantitative F-18-FDG PET/computed tomography parameters for prediction of grade in patients with renal cell carcinoma and the incremental value of diuretics.
Singh H; Arora G; Nayak B; Sharma A; Singh G; Kumari K; Jana S; Patel C; Pandey AK; Seth A; Kumar R
Nucl Med Commun; 2020 May; 41(5):485-493. PubMed ID: 32168262
[TBL] [Abstract][Full Text] [Related]
24. Role of 18F-FDG PET/CT in the assessment of therapy response and clinical outcome in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors or immunotherapy.
Tatar G; Alçin G; Şengül Samanci N; Erol Fenercioglu Ö; Beyhan E; Çermik TF
Nucl Med Commun; 2022 Jun; 43(6):701-709. PubMed ID: 35362692
[TBL] [Abstract][Full Text] [Related]
25. Imaging of renal cell carcinoma in patients with acquired cystic disease of the kidney: comparison
Kitajima K; Yamamoto S; Kawanaka Y; Katsuura T; Fujita M; Nakanishi Y; Yamada Y; Hashimoto T; Suzuki T; Go S; Kanematsu A; Nojima M; Yamakado K
Jpn J Radiol; 2019 Feb; 37(2):165-177. PubMed ID: 30377936
[TBL] [Abstract][Full Text] [Related]
26. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study.
Vercellino L; Bousquet G; Baillet G; Barré E; Mathieu O; Just PA; Desgrandchamps F; Misset JL; Hindié E; Moretti JL
Cancer Biother Radiopharm; 2009 Feb; 24(1):137-44. PubMed ID: 19243256
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated
Kelly-Morland C; Rudman S; Nathan P; Mallett S; Montana G; Cook G; Goh V
BMC Cancer; 2017 Jun; 17(1):392. PubMed ID: 28578690
[TBL] [Abstract][Full Text] [Related]
28. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
29. Elevated tumor-to-liver standardized uptake value ratio (TLR) from preoperative
Wu C; Cui Y; Zhao Y; Chen X; Liao X; Di L; Yin L; Liu M; Wang R
Eur J Radiol; 2020 Oct; 131():109218. PubMed ID: 32882538
[TBL] [Abstract][Full Text] [Related]
30. FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.
Chen JL; Appelbaum DE; Kocherginsky M; Cowey CL; Rathmell WK; McDermott DF; Stadler WM
Cancer Med; 2013 Aug; 2(4):545-52. PubMed ID: 24156027
[TBL] [Abstract][Full Text] [Related]
31. FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma.
Nakaigawa N; Kondo K; Tateishi U; Minamimoto R; Kaneta T; Namura K; Ueno D; Kobayashi K; Kishida T; Ikeda I; Hasumi H; Makiyama K; Kubota Y; Inoue T; Yao M
BMC Cancer; 2016 Feb; 16():67. PubMed ID: 26857818
[TBL] [Abstract][Full Text] [Related]
32. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.
Horn KP; Yap JT; Agarwal N; Morton KA; Kadrmas DJ; Beardmore B; Butterfield RI; Boucher K; Hoffman JM
Cancer Imaging; 2015 Sep; 15(1):15. PubMed ID: 26335224
[TBL] [Abstract][Full Text] [Related]
33. Clinical utility of
Nakamoto Y; Ishimori T; Shimizu Y; Sano K; Togashi K
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1524-1530. PubMed ID: 30847538
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma.
Minamimoto R; Barkhodari A; Harshman L; Srinivas S; Quon A
PLoS One; 2016; 11(4):e0153321. PubMed ID: 27123976
[TBL] [Abstract][Full Text] [Related]
35. Comparison of 18F-DCFPyL and 18F-FDG PET/computed tomography for the restaging of clear cell renal cell carcinoma: preliminary results of 15 patients.
Liu Y; Wang G; Yu H; Wu Y; Lin M; Gao J; Xu B
Nucl Med Commun; 2020 Dec; 41(12):1299-1305. PubMed ID: 32941403
[TBL] [Abstract][Full Text] [Related]
36. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
[TBL] [Abstract][Full Text] [Related]
37. Differentiating renal pelvic cancer from renal cell carcinoma with 18-fluorodeoxyglucose positron emission tomography-computed tomography.
Dursun M; Ozbek E; Otunctemur A; Besiroglu H
J Cancer Res Ther; 2021; 17(4):901-905. PubMed ID: 34528539
[TBL] [Abstract][Full Text] [Related]
38. Complete Response of a Patient With Metastatic Sarcomatoid Renal Cell Carcinoma to a Programmed Death-1 Checkpoint Inhibitor.
El Mouallem N; Smith SC; Paul AK
J Oncol Pract; 2018 Aug; 14(8):511-513. PubMed ID: 29920137
[No Abstract] [Full Text] [Related]
39. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer.
Kayani I; Avril N; Bomanji J; Chowdhury S; Rockall A; Sahdev A; Nathan P; Wilson P; Shamash J; Sharpe K; Lim L; Dickson J; Ell P; Reynolds A; Powles T
Clin Cancer Res; 2011 Sep; 17(18):6021-8. PubMed ID: 21742806
[TBL] [Abstract][Full Text] [Related]
40.
Toriihara A; Duan H; Thompson HM; Park S; Hatami N; Baratto L; Fan AC; Iagaru A
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1518-1523. PubMed ID: 30850872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
